Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
Präklinische Daten zeigen die Wirksamkeit von MKK4-Inhibitoren im Bereich der Leberregeneration sowie experimentellen Modellen aktuer und chronischer Lebererkrankungen...
Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies...
Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies which he successfully established...
HepaRegeniX entwickelt ein neues und einzigartiges therapeutisches Konzept zur Behandlung von Lebererkrankungen, basierend auf einer Entdeckung von Prof. Lars Zender und seiner Forschungsgruppe...
HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group...
